Targeting prostate cancer with specialized drug activation
Official title: Activation of Drug and Biologic Conjugates by Click Chemistry and their Tumor-selective Targeting for Prostate Cancer Suppression
Funded at University of Texas Hlth Science Center · NIH-11049022 · Data updated 2026-11-12
This study is exploring a new way to treat advanced prostate cancer by using a special drug that only targets cancer cells, aiming to kill the cancer without hurting healthy cells, and it's designed for men dealing with this tough condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $178,819 |
| NIH project number | 5R21CA289167-02 |
| Project ID | NIH-11049022 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with castration-resistant prostate cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have castration-resistant prostate cancer may not benefit from this research.
What this research studies
This research investigates a new method to treat advanced prostate cancer by activating a special drug only within tumor cells. The approach uses a technique called click chemistry to release the drug in cancerous tissues while minimizing harm to healthy cells. By focusing on a compound that reacts with substances found in cancer cells, the goal is to effectively destroy cancer cells without the side effects typically associated with chemotherapy. This study will test the effectiveness of these drug conjugates in preclinical models of castration-resistant prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with advanced prostate cancer, reducing side effects and improving outcomes.
How similar studies have gone: Previous research has shown promise in using targeted drug delivery systems in cancer treatment, suggesting that this approach may also be effective.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Chatterjee, Bandana — University of Texas Hlth Science Center
- Study coordinator: Chatterjee, Bandana
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.